Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Truly amazing Palaces: Which Is Your Number one? - 2Scientists solve the mystery of 'impossible' merger of 'forbidden' black holes
- 31,000-mile Saharan dust storm, from the sky and from the ground
- 4Four Dead in Last Month From Animal Attacks in Nepal
- 5South America's Memorable Destinations: A Movement Guide
- Court clears Beersheba assault suspect of link to Haymanut Kasau disappearance, extends detention
- New movies to watch this weekend: See 'The Drama' in theaters, rent 'Wuthering Heights,' stream 'Pizza Movie' on Hulu
- How will the universe end?
- New movies to watch this week: See 'Marty Supreme' in theaters, rent 'Springsteen: Deliver Me from Nowhere,' stream 'Cover-Up' on Netflix
- Haunting Giant Squid Surfaces in Japan and Devours Its Prey (Video)
- Discussion on deployment of foreign troops ongoing, two sources tell 'Post'
- Pacific voyagers’ remarkable environmental knowledge allowed for long-distance navigation without Western technology
- From Educational Loans to Obligation Free: Independence from the rat race Accomplished
- Czech Republic's new premier: No money for Ukraine
